Etonogestrel Implants Protect Ovarian Reserve Function in Systemic Lupus Erythematosus
Status:
Not yet recruiting
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
This clinical trial aims to test in female patients with systemic lupus erythematosus (SLE).
The main question it seeks to answer is whether etonogestrel implants can protect ovarian
reserve function in patients with SLE. Participants will be randomly divided into a test
group and a control group. The test group will be implanted subcutaneously with etongestrel
for one year. Researchers won't intervene in the control group. After three months of
drug-eluting, researchers will compare measures of ovarian reserve function in the test and
control groups to see if etonogestrel implants can protect ovarian reserve function in
patients with SLE.